Innovative Technology 4DMedical's proprietary XV technology offers unique and highly visual lung function imaging, which can be leveraged to differentiate their offerings in markets seeking advanced respiratory diagnostics.

Regulatory Milestone The recent FDA 510(k) clearance for CT:VQ™ enables the company to expand its reach within the US healthcare market, creating opportunities for partnerships with hospitals and imaging centers seeking FDA-approved solutions.

Market Reimbursement Medicare reimbursement approval for CT:VQ™ broadens access to non-contrast ventilation–perfusion imaging, increasing demand among clinicians and health systems looking for innovative and reimbursable imaging modalities.

Growth Potential With an estimated revenue range of $10M to $25M and recent funding of $15M, 4DMedical is positioned for expansion into new markets, making it a promising partner for joint ventures or distribution agreements.

Strategic Positioning The company's focus on disruptive respiratory imaging technology, combined with its recent regulatory approvals and reimbursement pathways, provides a compelling value proposition for healthcare providers wanting to enhance respiratory diagnostics.